Imaging EGFR-positive cancers using a new PET method
Official title: Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR Positive Cancers by Positron Emission Tomography (PET)
Run by University of Saskatchewan · NCT04235114 · Data updated 2026-11-12
This study is testing a new imaging method to see if it can help doctors spot certain cancers that have a lot of a protein called EGFR, which could help identify patients who might benefit from specific cancer treatments.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 14 (estimated) |
| Sponsor | University of Saskatchewan Academic / other |
| Drugs / interventions | nimotuzumab |
| Locations | 1 site (Saskatoon, Saskatchewan) |
| Status | Recruiting |
| Started | February 1, 2020 |
| Main results expected | September 2026 |
| Study ends | December 2026 |
| Registry record updated | January 9, 2024 |
| Trial ID | NCT04235114 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 to 80 with EGFR-positive cancers and tumors measuring at least 1.5 cm.
✕Probably not a fit
Patients who are unable to tolerate 60 minutes of PET imaging or those who have previously received anti-EGFR antibody treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the use of 89Zr-DFO-nimotuzumab for non-invasive imaging of cancers that over-express the Epidermal Growth Factor Receptor (EGFR), such as lung and colorectal cancers. By utilizing Positron Emission Tomography (PET) and Computerized Tomography (CT), the study aims to determine the feasibility of visualizing EGFR-positive tumors, which could help identify patients likely to benefit from anti-EGFR treatments. The trial will assess the accumulation of the imaging agent in tumors and establish the optimal timing for imaging. This approach seeks to improve the reliability of EGFR expression monitoring compared to existing invasive methods.
Why it matters
Potential benefit: If successful, this method could lead to more accurate and less invasive identification of patients who would benefit from targeted anti-EGFR therapies.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in non-invasive imaging techniques for cancer detection.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female between 18 and 80 years old. * EGFR-positive cancer defined by a board certified pathologist * Primary or metastatic lesion size \>= 1.5 cm as determined by imaging studies (ultrasonography, mammography, CT or MRI) or physical examination. * Able to give informed consent. * Not currently pregnant or nursing: If female subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for \> 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test is negative when taken within the 24 h before administration of 89Zr-DFO-nimotuzumab. * WHO performance status of 0 - 2 * Patients naïve to anti-EGFR antibodies treatment. Exclusion Criteria: * Unable to tolerate 60 min of PET imaging per session.
Where it's running
-
Royal University Hospital
Saskatoon, Saskatchewan, Canada Recruiting
Study contacts
- Study coordinator: Rajan Rakheja, MD
- Email: rajan.rakheja@gmail.com
- Phone: 306-655-2932
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
Social prescriptions and micro-learning to improve cancer care
This study tests a multicomponent program using social prescriptions and short online learning to help cancer patients and their chosen support persons in Germany.
-
Personal health app in young-to-midlife adults in Hong Kong
This trial tests whether the Wellnuts self-health assessment app helps asymptomatic adults in Hong Kong become more health-aware and proactive about care, compared with standard online health resources.
-
Precision navigation to boost cancer screening participation in high-risk communities
This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.
-
LRRC15-targeted PET imaging for more precise diagnosis and staging of pancreatic, breast, lung, sarcoma and head-and-neck cancers
This project tests whether an LRRC15-targeted PET scan can better detect and stage LRRC15-expressing cancers and measures how the tracer behaves in healthy adults.
-
AI language tools to help tumor care teams write MDT reports
We will test whether AI language tools can help junior cancer doctors write MDT diagnosis and treatment reports more accurately and faster.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.